<DOC>
	<DOCNO>NCT02881346</DOCNO>
	<brief_summary>This study aim assess Enstilar® aerosol foam performs daily real-life practice regard effectiveness convenience application psoriasis plaque body extremity . In addition profile patient prescribed Enstilar® described , preceeding , concomitant follow-up management map . The study conduct 100 dermatology clinic Germany ,</brief_summary>
	<brief_title>Efficacy Tolerability Enstilar® Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>≥ 18 year age Psoriasis vulgaris Lesions trunk and/or extremity least mild severity Treatment Enstilar® plan Signed inform consent participate Enrolled interventional clinical trial Ongoing recent treatment systemic psoriasis Ongoing recent treatment UVtherapy Ongoing previous treatment Enstilar® Psoriasis scalp Other form psoriasis , e.g . erythrodermic pustular psoriasis More 30 % surface area affect psoriasis Any contraindication know allergy Enstilar® ingredient Incapacitated patient institutionalize care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis vulgaris</keyword>
	<keyword>Plaque</keyword>
	<keyword>Topical</keyword>
	<keyword>Calcipotriol</keyword>
	<keyword>Foam</keyword>
	<keyword>Spray</keyword>
</DOC>